EP0154316B1
(fr)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Lymphokine chimiquement modifiée et son procédé de préparation
|
US5023252A
(en)
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
US4992445A
(en)
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
US5001139A
(en)
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
EP0401384B1
(fr)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5625825A
(en)
|
1993-10-21 |
1997-04-29 |
Lsi Logic Corporation |
Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
|
EP2261229A3
(fr)
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Modification par glycosylation d'anticorps aux fins d'amélioration de la cytotoxicité cellulaire dépendant des anticorps
|
PT1071752E
(pt)
|
1998-04-21 |
2003-11-28 |
Micromet Ag |
Polipeptidos especificos para cd19xcd3 e suas utilizacoes
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
ES2420835T3
(es)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de las moléculas inmunofuncionales
|
NZ517372A
(en)
|
1999-07-29 |
2004-04-30 |
Medarex Inc |
Human monoclonal antibodies to HER2/neu
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
WO2002077029A2
(fr)
|
2000-11-07 |
2002-10-03 |
City Of Hope |
Cellules immunitaires specifiques a cd19 redirigees
|
CN101940189A
(zh)
|
2000-11-30 |
2011-01-12 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
US20040136908A1
(en)
|
2001-04-09 |
2004-07-15 |
Olson William C. |
Anti-cd19 immunotoxins
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
DE60127143T2
(de)
|
2001-11-14 |
2007-11-15 |
Affimed Therapeutics Ag |
Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
|
DE10163755A1
(de)
|
2001-12-27 |
2004-01-08 |
Immugenics Ag |
Tumor-Peptidantigene aus humanem CD19-Protein
|
US20080260731A1
(en)
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
AU2002950778A0
(en)
|
2002-08-15 |
2002-09-12 |
The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland |
A method of characterizing dendritic cells
|
MXPA05012080A
(es)
|
2003-05-08 |
2006-02-22 |
Xcyte Therapies Inc |
Generacion y aislamiento de celulas t especificas al antigeno.
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
RU2005141512A
(ru)
|
2003-05-31 |
2007-07-20 |
Микромет Аг (De) |
Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
|
WO2005014599A1
(fr)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes
|
WO2005005429A1
(fr)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes
|
WO2005007673A2
(fr)
|
2003-07-03 |
2005-01-27 |
Rush University Medical Center |
Peptides immunogenes
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
AU2004282219C1
(en)
|
2003-10-15 |
2009-12-17 |
Osi Pharmaceuticals, Inc. |
Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
CA2597924C
(fr)
|
2005-02-15 |
2018-10-02 |
Duke University |
Anticorps anti-cd19 et leur utilisation en oncologie
|
US8444973B2
(en)
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
CA2607281C
(fr)
|
2005-05-05 |
2023-10-03 |
Duke University |
Traitements des maladies auto-immunes par anticorps anti-cd19
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
EP1904101A4
(fr)
|
2005-06-08 |
2011-06-15 |
Univ Duke |
Therapie a anticorps diriges contre cd19 a des fins de transplantation
|
WO2007002223A2
(fr)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Anticorps cd19 et utilisations
|
EP1907424B1
(fr)
|
2005-07-01 |
2015-07-29 |
E. R. Squibb & Sons, L.L.C. |
Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
|
US20070166306A1
(en)
|
2006-01-17 |
2007-07-19 |
Fey Georg H M |
Anti-CD19 antibody composition and method
|
US20090220501A1
(en)
|
2006-01-30 |
2009-09-03 |
Fey Georg H |
Anti-CD19 Antibody, Immunotoxin and Treatment Method
|
CA2658557C
(fr)
|
2006-08-14 |
2015-12-01 |
Xencor, Inc. |
Anticorps optimises ciblant cd19
|
PL2066349T3
(pl)
|
2006-09-08 |
2012-09-28 |
Medimmune Llc |
Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
WO2008109493A2
(fr)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Composés d'acides nucléiques conçus pour inhiber l'expression du gène cd19 et utilisations de ceux-ci
|
PL2170959T3
(pl)
|
2007-06-18 |
2014-03-31 |
Merck Sharp & Dohme |
Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
US7968687B2
(en)
|
2007-10-19 |
2011-06-28 |
Seattle Genetics, Inc. |
CD19 binding agents and uses thereof
|
US7894450B2
(en)
|
2007-12-31 |
2011-02-22 |
Nortel Network, Ltd. |
Implementation of VPNs over a link state protocol controlled ethernet network
|
DK2240451T3
(da)
|
2008-01-04 |
2017-11-20 |
Intellikine Llc |
Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
CA2986640C
(fr)
|
2008-06-27 |
2019-03-26 |
Celgene Avilomics Research, Inc. |
Composes hetero-aryles et leurs utilisations
|
PL2376535T3
(pl)
|
2008-12-09 |
2017-09-29 |
F.Hoffmann-La Roche Ag |
Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
|
EP2398829A2
(fr)
|
2009-02-23 |
2011-12-28 |
Glenmark Pharmaceuticals S.A. |
Anticorps humanisés qui se fixent au cd19 et leurs utilisations
|
WO2010132532A1
(fr)
|
2009-05-15 |
2010-11-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps réagissant à la surface des lymphocytes b
|
CN102711822A
(zh)
|
2009-10-27 |
2012-10-03 |
米克罗麦特股份公司 |
用于施用CD19xCD3双特异性抗体的给药方案
|
SI3279215T1
(sl)
|
2009-11-24 |
2020-07-31 |
Medimmune Limited |
Usmerjena vezavna sredstva proti B7-H1
|
WO2011147834A1
(fr)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Anticorps contre cd19 et utilisations associées
|
NZ772688A
(en)
*
|
2010-06-03 |
2022-09-30 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
NZ605988A
(en)
|
2010-06-23 |
2014-11-28 |
Hanmi Science Co Ltd |
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
KR20130099040A
(ko)
|
2010-08-10 |
2013-09-05 |
셀진 아빌로믹스 리서치, 인코포레이티드 |
Btk 억제제의 베실레이트 염
|
US8529202B2
(en)
|
2010-10-12 |
2013-09-10 |
General Electric Company |
System and method for turbine compartment ventilation
|
US20120141505A1
(en)
|
2010-11-01 |
2012-06-07 |
Fatih M. Uckun |
Cd19-ligand and use
|
SG10201510092QA
(en)
|
2010-12-09 |
2016-01-28 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
CA2831843A1
(fr)
|
2011-04-04 |
2012-10-11 |
Pharmascience Inc. |
Inhibiteurs de proteine kinase
|
CA2760174A1
(fr)
|
2011-12-01 |
2013-06-01 |
Pharmascience Inc. |
Inhibiteurs de proteines kinases et leurs utilisations
|
WO2012146394A1
(fr)
|
2011-04-28 |
2012-11-01 |
Amgen Research (Munich) Gmbh |
Régime posologique pour l'administration d'un anticorps bispécifique cd19xcd3 à des patients à risque d'éventuels effets indésirables
|
KR102052670B1
(ko)
|
2011-05-17 |
2019-12-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키나아제 저해제
|
US9096642B2
(en)
|
2011-06-08 |
2015-08-04 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
US20140155406A1
(en)
|
2011-07-19 |
2014-06-05 |
Petrus Antonius De Adrianus Man |
4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk inhibitors
|
MY192354A
(en)
*
|
2011-07-19 |
2022-08-17 |
Merck Sharp & Dohme |
4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
|
CA2840018C
(fr)
|
2011-07-24 |
2019-07-16 |
Curetech Ltd. |
Variants d'anticorps monoclonaux immunomodulateurs humanises
|
CN107266584B
(zh)
|
2011-07-29 |
2022-05-13 |
宾夕法尼亚大学董事会 |
转换共刺激受体
|
EP2550975A1
(fr)
|
2011-07-29 |
2013-01-30 |
Sanofi |
Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
EA032463B1
(ru)
*
|
2011-10-19 |
2019-05-31 |
Фармасайкликс Элэлси |
Применение ингибиторов тирозинкиназы брутона (втк)
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
RU2615999C2
(ru)
|
2011-11-29 |
2017-04-12 |
Оно Фармасьютикал Ко., Лтд. |
Гидрохлорид производного пуринона
|
EP3594245A1
(fr)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Récepteurs d'antigènes chimériques bispécifiques et leurs utilisations thérapeutiques
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
AU2013235726B2
(en)
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
KR20140142736A
(ko)
|
2012-03-29 |
2014-12-12 |
오리진 디스커버리 테크놀로지스 리미티드 |
인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물
|
SI4019041T1
(sl)
|
2012-07-13 |
2023-04-28 |
The Trustees Of The University Of Pennsylvania |
Obladovanje toksičnosti za protitumorsko delovanje CARS
|
CN105008516A
(zh)
|
2012-08-13 |
2015-10-28 |
人类起源公司 |
自然杀伤细胞及其用途
|
CN111139256A
(zh)
|
2013-02-20 |
2020-05-12 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
JP6204568B2
(ja)
|
2013-04-25 |
2017-09-27 |
ベイジーン,リミテッド |
タンパク質キナーゼ阻害剤としての縮合複素環化合物
|
WO2014186469A2
(fr)
|
2013-05-14 |
2014-11-20 |
Board Of Regents, The University Of Texas System |
Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car)
|
US20150005277A1
(en)
|
2013-06-28 |
2015-01-01 |
Beigene, Ltd. |
Protein Kinase Inhibitors and Uses Thereof
|
HUP1300432A2
(hu)
|
2013-07-10 |
2015-01-28 |
Tamas Kardos |
Downhill kerékpár szerkezet javított felfüggesztéssel
|
JP2016532711A
(ja)
|
2013-09-06 |
2016-10-20 |
オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited |
免疫調節剤としての1,3,4−オキサジアゾール及び1,3,4−チアジアゾールの誘導体
|
PL3363790T3
(pl)
|
2013-09-06 |
2020-07-27 |
Aurigene Discovery Technologies Limited |
Pochodne 1,2,4-oksadiazolu jako immunomodulatory
|
WO2015036927A1
(fr)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Dérivés peptidomimétiques d'immunomodulation
|
MX2016003292A
(es)
|
2013-09-13 |
2016-06-24 |
Beigene Ltd |
Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos.
|
WO2015110923A2
(fr)
*
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
|
RU2718542C2
(ru)
*
|
2014-04-07 |
2020-04-08 |
Новартис Аг |
Лечение злокачественной опухоли с использованием химерного рецептора антигена против cd19
|
WO2016164580A1
(fr)
*
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Thérapie combinée par récepteur antigénique chimérique et dérivés d'amino pyrimidine
|